腫瘤營養市場 - 按癌症類型（食道、肝癌、胰臟、胃）、產品類型（蛋白質、維生素、礦物質）、配方（標準、元素）、給藥途徑、劑量類型（液體、粉末）、最終用途 - 2024 - 2032 年全球預測

Oncology Nutrition Market - By Cancer Type (Esophageal, Liver, Pancreatic, Stomach), Product Type (Protein, Vitamin, Mineral), Formulation (Standard, Elemental), Route of Administration, Dosage Type (Liquid, Powder), End-use- Global Forecast 2024 - 2032

出版日期: 2024年04月12日 | 出版商:

Global Market Insights Inc. | 英文 140 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

隨著人們對營養在癌症治療中至關重要作用的認知不斷增強，以及醫學研究的進步，腫瘤營養市場規模從 2024 年到 2032 年將達到 8.1% 的複合年成長率。隨著醫療保健提供者和患者認知到客製化營養支持在管理治療副作用和改善結果方面的好處，對專門腫瘤營養產品的需求正在上升。正在進行的研究繼續完善營養策略，強調其對患者康復和生活品質的影響。這些因素共同推動了該領域的創新和投資，促進市場成長並提高患者護理標準。

例如，2024 年 6 月，DAE 與 IDRS Labs 合作推出了“AKTOCYTE”，這是一種針對接受放射治療的癌症患者的營養保健品，旨在改善他們在治療期間的生活品質。它顯示了支持性護理策略的創新趨勢，旨在提高患者的生活品質並更有效地應對與治療相關的挑戰。此外，此類措施強調了科研機構和產業之間加強合作，以滿足腫瘤學的特定營養需求，從而有可能推動該市場的進一步成長和發展。

腫瘤營養產業根據癌症類型、產品類型、配方、給藥途徑、劑量類型、最終用途和地區進行分類。

由於全球食道癌發生率較高，到 2032 年，食道部分將取得顯著進展。食道癌患者經常出現吞嚥困難，導致營養攝取和消化面臨挑戰。這需要根據他們的需求提供專門的營養支持，從而推動對腫瘤營養產品的需求。此外，醫學治療的進步以及人們對營養支持在癌症護理中重要性的認知的提高，進一步推動了食道腫瘤營養市場的成長。

到 2032 年，維生素和礦物質領域將經歷顯著的好轉，因為這些營養素在癌症治療期間支持免疫功能和整體健康方面發揮關鍵作用。患者通常需要補充劑來抵消治療相關的副作用並支持康復。醫療保健提供者對個人化營養以及維生素和礦物質在增強治療效果方面的功效的認知不斷提高，進一步推動了市場成長。針對腫瘤患者量身定做的營養配方的持續創新凸顯了該細分市場在不斷發展的癌症護理領域中的關鍵作用。

由於人口快速成長、癌症盛行率上升以及醫療保健支出不斷增加，亞太地區腫瘤營養產業佔有率在 2024 年和 2032 年將錄得顯著的複合年成長率。此外，該地區不斷壯大的中產階級和不斷改善的醫療基礎設施正在推動癌症患者對專門營養產品的需求。本地和國際參與者對研發的大量投資也促進了市場成長。該地區強勁的經濟成長和城市化進一步使亞太地區成為腫瘤營養市場的主要貢獻者。

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 歐洲其他地區
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 中東和非洲其他地區

第 12 章：公司簡介

Abbott Laboratories
Baxter International Inc.
B. Braun Melsungen AG
Danone (Nutricia)
Fresenius SE & Co. KGaA
Grifol S.A.
Hormel Foods Corporation
Meiji Holdings Co., Ltd.
Medtrition Inc.
Nestle S.A.
Victus, Inc.

簡介目錄

Product Code: 9015

Oncology Nutrition Market size will reach an 8.1% CAGR from 2024 to 2032, fueled by the increasing awareness of nutrition's crucial role in cancer treatment, coupled with advancements in medical research. As healthcare providers and patients recognize the benefits of tailored nutritional support in managing treatment side effects and improving outcomes, demand for specialized oncology nutrition products is rising. Ongoing research continues to refine nutritional strategies, highlighting their impact on patient recovery and quality of life. These factors collectively drive innovation and investment in the field, fostering market growth and improving patient care standards.

For instance, in June 2024, DAE, in partnership with IDRS Labs, introduced 'AKTOCYTE,' a nutraceutical for cancer patients undergoing radiotherapy aimed at improving their quality of life during treatment. It indicates a trend towards innovation in supportive care strategies aimed at enhancing patients' quality of life and managing treatment-related challenges more effectively. Moreover, such initiatives underscore increasing collaboration between scientific institutions and industry to address specific nutritional needs in oncology, potentially driving further growth and development in this market.

The oncology nutrition industry is divided based on cancer type, product type, formulation, route of administration, dosage type, end-use, and region.

The esophageal segment will garner noteworthy gains through 2032, owing to the high incidence of esophageal cancer worldwide. Patients with esophageal cancer often experience difficulties in swallowing, leading to challenges in nutrient intake and digestion. This necessitates specialized nutritional support tailored to their needs, driving the demand for oncology nutrition products. Additionally, advancements in medical treatments and increasing awareness about the importance of nutritional support in cancer care are further propelling the growth of the esophageal segment in the oncology nutrition market.

The vitamins and minerals segment will experience a significant upturn by 2032, driven by the critical role these nutrients play in supporting immune function and overall health during cancer treatment. Patients often require supplementation to counteract treatment-related side effects and support recovery. Increasing awareness among healthcare providers about personalized nutrition and the efficacy of vitamins and minerals in enhancing treatment outcomes further propels market growth. Continuous innovation in nutritional formulations tailored to oncology patients underscores the segment's pivotal role in the evolving landscape of cancer care.

Asia Pacific oncology nutrition industry share will record a notable CAGR during 2024 and 2032 due to its rapidly growing population, increasing prevalence of cancer, and rising healthcare expenditure. Additionally, the region's expanding middle class and improving healthcare infrastructure are driving demand for specialized nutritional products for cancer patients. Significant investments in research and development by local and international players are also bolstering market growth. The region's robust economic growth and urbanization further make the Asia Pacific a key contributor to the oncology nutrition market.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360-degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising incidence of cancer
  - 3.2.1.2 Growing awareness of nutrition's role in cancer care
  - 3.2.1.3 Growing geriatric population
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost of specialized oncology nutrition products
  - 3.2.2.2 Regulatory challenges
3.3 Growth potential analysis
3.4 Porter's analysis
3.5 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Company positioning matrix
4.4 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Cancer Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Head and neck cancer
5.3 Stomach and gastrointestinal cancer
5.4 Esophageal cancer
5.5 Liver cancer
5.6 Breast cancer
5.7 Pancreatic cancer
5.8 Lung cancer
5.9 Other cancer types

Chapter 6 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Vitamins and minerals
6.3 Proteins
6.4 Antioxidants
6.5 Other product types

Chapter 7 Market Estimates and Forecast, By Formulation, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Standard
7.3 Elemental

Chapter 8 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Oral
8.3 Parenteral

Chapter 9 Market Estimates and Forecast, By Dosage Type, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 Liquid
9.3 Powder
9.4 Other dosage types

Chapter 10 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

10.1 Key trends
10.2 Hospitals
10.3 Clinics
10.4 Homecare
10.5 Other end-users

Chapter 11 Market Estimates and Forecast, By Region, 2021- 2032 ($ Mn)

11.1 Key trends
11.2 North America
- 11.2.1 U.S.
- 11.2.2 Canada
11.3 Europe
- 11.3.1 Germany
- 11.3.2 UK
- 11.3.3 France
- 11.3.4 Spain
- 11.3.5 Italy
- 11.3.6 Rest of Europe
11.4 Asia Pacific
- 11.4.1 Japan
- 11.4.2 China
- 11.4.3 India
- 11.4.4 Australia
- 11.4.5 Rest of Asia Pacific
11.5 Latin America
- 11.5.1 Brazil
- 11.5.2 Mexico
- 11.5.3 Rest of Latin America
11.6 Middle East and Africa
- 11.6.1 South Africa
- 11.6.2 Saudi Arabia
- 11.6.3 Rest of Middle East and Africa